"With approximately $1.6 trillion in global sales, the pharmaceutical industry is a steadily growing sector driven by the rise of personalized medicine, the increase of chronic diseases, and an aging global population. At 24/7 Wall St., we have consistently believed that investing in the pharmaceutical industry offers our readers a range of potential opportunities. Plus, most across the investment world still consider the industry defensive, so it is not a bad idea, given the current market volatility."
"We mention this because three of the highest-yielding Dogs of the Dow are among the top companies in the pharmaceutical/healthcare sector, and all three trade at bargain levels. The best part is that all three have very different business models and product silos, so you don't duplicate exposure to the sector. The other two companies are perfect plays for a slowing economy where interest rates are poised to fall. All five of the dogs are rated Buy at top Wall Street firms."
The Dogs of the Dow strategy selects the ten highest-yielding dividend stocks in the Dow annually to maximize investment yields. Highest yields often reflect lower share prices, creating potential value opportunities. The Dow recently reached record highs, making high-yield dogs a possible contrarian dividend play into the fourth quarter and 2026. The pharmaceutical industry, with about $1.6 trillion in global sales, benefits from personalized medicine, rising chronic disease prevalence, and population aging, and is viewed as defensive during market volatility. Three of the five highest-yielding small dogs are major pharmaceutical/healthcare companies trading at bargain levels, while the other two suit a slowing-economy, falling-interest-rate scenario. All five carry Buy ratings and small-dog approaches have historically outperformed the broader Dow.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]